Accelerating NDA filing through faster carcinogenicity assessment
Drug Discovery World
MAY 10, 2023
Regulatory agencies such as the US Food & Drug Administration (FDA), European Medicines Agency (EMA), and the China National Medical Products Administration (NMPA) adhere to these guidelines and require that novel small molecule compounds intended for continuous or intermittent use undergo specific types of carcinogenicity testing studies.
52 
Let's personalize your content